DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy

DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy

Background: TIGIT is an immune checkpoint under investigation as therapeutic target. Understanding the regulation of TIGIT on an epigenetic level might support the development of companion biomarkers. Methods: We correlated TIGIT DNA methylation of single CpG sites with gene expression, signatures o...

Full description

Bibliographic Details
Main Authors: de Vos, L. (Author), Dietrich, D. (Author), Dietrich, J. (Author), Fietz, S. (Author), Fröhlich, A. (Author), Hoffmann, F. (Author), Kuster, P. (Author), Landsberg, J. (Author), Niebel, D. (Author), Ramírez Valladolid, S. (Author), Saavedra, G. (Author), Sirokay, J. (Author), Strieth, S. (Author), Vogt, T.J (Author), Zarbl, R. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Biomarker
DNA methylation
DNA Methylation
Epigenesis, Genetic
genetic epigenesis
genetics
human
Humans
immunoglobulin receptor
immunotherapy
Immunotherapy
melanoma
Melanoma
messenger RNA
metabolism
prognosis
Prognosis
Progression-Free Survival
Receptors, Immunologic
RNA, Messenger
T Cell Ig and ITIM Domain (TIGIT)
TIGIT protein, human
tumor microenvironment
Tumor Microenvironment
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items